Ness Technologies Awarded $2 Million Deployment Project by Teva Czech Industries

Ness Technologies Awarded $2 Million Deployment Project by Teva Czech Industries
 
 Project Will Help Teva Czech Industries Triple Exports to the United States and Western European Markets
PRAGUE, April 26, 2010 /PRNewswire-FirstCall/ -- Ness Technologies, Inc. (NASDAQ: NSTC and TASE: NSTC), a global provider of information technology solutions and services, announced today the start of an Oracle(R) E-Business Suite implementation at Teva Czech Industries s.r.o., a provider of pharmaceutical products. The new system will handle financial and logistics issues, replacing a current QAD MFG/Pro system. The project, which is valued at $2 million, is targeted to go into production on January 1, 2011. Ness will support the project through the end of April 2011. Teva Czech Industries is part of Teva Pharmaceutical Industries, a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients.

Teva Pharmaceutical Industries selected Ness, a leading provider of IT services and solutions in Central and Eastern Europe, an Oracle Platinum Partner and one of the region's leaders in the manufacturing segment, based on its reputation as a reliable and proven partner who could completely fulfill Teva's expectations regarding the new enterprise system. Key factors for Teva were Ness' experience in similar international projects, its professional approach and its large team of dedicated Oracle E-Business Suite experts in Central and Eastern Europe.

"Our company is strongly export focused, exporting over 80% of our production, including to the highly complex markets in the U.S. and Western Europe," said Jiri Urbanec, CEO of Teva Czech Industries. "Thanks to the launch of a new plant for solid pharmaceutical drugs this year, we expect that our exports will increase more than three times. In order to produce four billion tablets annually for one of the toughest markets in the world, we need to manage our financial and logistics processes with world-class tools. The new system will not only simplify and optimize Teva's production plant in Opava, Czech Republic, and its commercial units in Prague, Czech Republic, and Bratislava, Slovakia, but it will also connect the two European countries to the Israeli offices of its parent company, Teva Pharmaceutical Industries."

"Winning this important project confirms our dominant position as a provider of Oracle E-Business Suite implementation services in the Czech Republic. This is one of the most important projects of this type," said Mirko Kalous, MBA, CEO of Ness Czech. "We have been engaged with the Oracle E-Business Suite since its entry into the Czech market 1993, when we participated in the localization and the first implementations of the solution."

Ness has deployed and operated similar solutions for other leading companies in their sectors, such as Vitkovice and Dalkia Czech Republic. Manufacturing is an important sector for Ness, where the company has a wide domain expertise. This expertise will be used by Ness in the Teva project. The cooperation between Teva and Ness is not limited only to the Czech market; as a regional partner Ness is able to support Teva's strategy throughout the whole region.

The Oracle E-Business Suite is a comprehensive suite of integrated, global business applications, which provides a complete, integrated business intelligence portfolio, the most adaptable global business platform, and the most customer-focused applications strategy. The Oracle E-Business Suite enables, for example, asset life cycle management, customer relationship management, enterprise resource planning, supply chain management and more.

About Ness Technologies

Ness Technologies (NASDAQ: NSTC and TASE: NSTC) is a global provider of IT and business services and solutions with specialized expertise in software product engineering; system integration, application development and consulting; and software distribution. Ness delivers its portfolio of solutions and services using a global delivery model combining offshore, near-shore and local teams. With about 7,800 employees, Ness maintains operations in 18 countries, and partners with numerous software and hardware vendors worldwide. For more information about Ness Technologies, visit http://www.ness.com.

About Teva Czech Industries

Teva Czech Industries, based in Opava, Czech Republic, is a leading pharmaceutical manufacturer with a long history. Its broad portfolio includes generic medicines, over the counter drugs, active pharmaceutical ingredients and plant extracts. The company's products meet recognized quality standards and are exported to many countries around the world, including the United States and Western Europe. Teva Czech Industries employs more than 1,000 employees, helping the company reach its achievements and ambitious goals. In 2006 the company became part of Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is a leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe. For more information about Teva, visit http://www.tevapharm.com.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often are preceded by words such as "believes," "expects," "may," "anticipates," "plans," "intends," "assumes," "will" or similar expressions. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Ness' actual results could differ materially from those anticipated in these forward looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in Ness' Annual Report of Form 10-K filed with the Securities and Exchange Commission on March 15, 2010. Ness is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of such changes, new information, subsequent events or otherwise.

Trademarks

    Oracle and Java are registered trademarks of Oracle Corporation and/or
its affiliates.

    Media Contact:
    David Kanaan
    Intl: +972-54-425-5307
    Email: [email protected]

    Investor Relations Contact:
    Drew Wright
    USA: +1-201-488-3262
    Email: [email protected]


SOURCE Ness Technologies Inc

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.